Acacia Pharma lists on Euronext Brussels



Acacia Pharma to join the largest franchise of Life Science issuers in Europe

Brussels, 5 March 2018 – Euronext today celebrated the listing of Acacia Pharma, a UK-based hospital pharmaceutical company on its Brussels market (Compartment B). This operation demonstrates the benefits offered by Euronext’s European Tech SME initiative as well as the attractiveness of Euronext as the leading venue for Biotech and Pharma companies in Europe. With this operation, Acacia Pharma joins a large franchise of 89 Life Science companies (52 Biotech and 37 Medtech companies) currently listed on Euronext’s markets, representing a total market capitalisation of €23.6 billion.

Acacia Pharma is focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. It has identified important unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.

The Group’s lead project, BAREMSIS® for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies and an NDA has been accepted for filing by the US FDA for marketing approval with a target review date of 5 October 2018. BAREMSIS has the potential to become an important new option for the 16 million surgical patients in the US annually who suffer PONV despite having received prior prophylaxis with standard antiemetics, and in preventing PONV in combination with standard antiemetics in the 18 million patients in the US annually who are at high risk of developing it.

The company’s sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN.   

The proceeds of the Global Offer are expected to allow Acacia Pharma to build the sales and marketing infrastructure and undertake marketing, supply chain and other preparatory activities ready to launch BAREMSIS for the treatment and prevention of PONV, to the hospital market in early 2019 (assuming approval in late 2018). Additionally, the proceeds will be applied to continue the development of APD403for the management of CINV.

With the Offer Price at €3,60 per share, Acacia Pharma’s total offering size amounts to approximately €40 million. With a total of 52,919,061 million shares admitted to trading, Acacia Pharma (ticker: ACPH) has an initial market capitalisation before opening of approximately €190 million.

Dr Julian Gilbert, CEO and founder of Acacia Pharma, said: “The successful completion of our Initial Global Offering is a significant milestone for Acacia Pharma. The new funds provide us with a strong basis from which to build a successful US hospital-focused pharmaceutical business around our two late-stage products, BAREMSIS and APD403, and their potential to improve the lives of millions of patients undergoing surgery or cancer therapy. We are very pleased that our business plan has resonated, and as a result we have added many high-quality investors in the UK, Europe and the US to our shareholder base. Through the successful Global Offer and new listing on Euronext, we believe that Acacia Pharma is now well-positioned to deliver its plans and look forward to the next phase in the company’s development.” 

Bank Degroof Petercam NV/SA and RBC Europe Limited acted as Joint Global Coordinators and Joint Bookrunners in connection with the Global Offer. Bank Degroof Petercam NV/SA acts as Stabilisation Manager on behalf of the Joint Global Coordinators.

To celebrate Acacia Pharma’s first day of conditional trading , Dr Julian Gilbert, CEO and founder of Acacia Pharma, rang the bell to open the markets at Euronext Brussels.

Attachments Available Languages
Download press releaseen

About Euronext
Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end December 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base.  Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market). For the latest news, find us on Twitter  ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2018, Euronext N.V. - All rights reserved.